Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2006-10-04
2008-10-07
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S006120, C435S069100, C435S325000
Reexamination Certificate
active
07432047
ABSTRACT:
Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.
REFERENCES:
patent: 5248670 (1993-09-01), Draper et al.
patent: 5306619 (1994-04-01), Edwards et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5622861 (1997-04-01), Kaplan et al.
patent: 5738985 (1998-04-01), Miles et al.
patent: 6100089 (2000-08-01), Reddy et al.
patent: 6156496 (2000-12-01), Miles et al.
patent: 6174868 (2001-01-01), Anderson et al.
patent: 6284458 (2001-09-01), Anderson et al.
patent: 6623961 (2003-09-01), Miles et al.
patent: 6667152 (2003-12-01), Miles et al.
patent: 6777179 (2004-08-01), Miles et al.
patent: 6824976 (2004-11-01), Miles et al.
patent: 7045284 (2006-05-01), Miles et al.
patent: 7285383 (2007-10-01), Miles et al.
patent: 2004/0254140 (2004-12-01), Miles et al.
patent: 0 662 157 (1995-12-01), None
patent: WO 83/01451 (1983-04-01), None
patent: WO 92/14422 (1990-11-01), None
patent: WO 92/02639 (1992-02-01), None
patent: WO 92/03456 (1992-03-01), None
patent: WO 92/05286 (1992-04-01), None
patent: WO 93/03143 (1993-02-01), None
patent: WO 99/29350 (1999-06-01), None
patent: WO 00/06590 (2000-02-01), None
Agris et al., Biochem. 25:6268-6275 (1986).
Babiss et al., Mol. Cell. Biol. 5:2552-2558 (1985).
Bae et al., Virology 170:282-287 (1989).
Baroudy et al., Proc. Natl. Acad, Sci. USA 82:2143-2147 (1985).
Beattie et al., Virology 183:419-422 (1991).
Beck et al., Nucleic Acids Res. 11:7873-7885 (1983).
Biegalke & Gebaile Virology 177:657-667 (1990).
Black et al., J. Virology 67:791-800 (1993).
Boothroyd et al., Nature 290:800-802 (1981).
Boothroyd et al., Gene 17:153-161 (1982).
Borman et al.,J. Gen. Virol. 74:1775 (1993).
Borman and Jackson, Virology 188:685 (1992).
Borovjagin et al., “A Factor that Specifically Binds to the 5′-Untranslated Region of Encephalomyocarditis Virus RNA,” FEBS Lett. 261:237-240 (1990).
Borovjagin et al., “RNA-Protein Interactions With the Internal ranslation Initiation Region of the Encephalomyocarditis Virus RNA,” Nucl. Acids Res., 19:4999-5005 (1991).
Bouloy et al., Proc. Natl. Acad. Sci. USA 75:4886-4890 (1978).
Branch, A.D., A good antisence molecule is hard to find, TIBS Feb. 23, 1998, pp. 45-50.
Brown et al., J. Virol. 65:5828-5838 (1991).
Brown-Driver, V. et al., “Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides.” Antisense Nucleic Acid Drug Dev. Apr. 1999;9(2):145-54.
Callahan P et al., Proc. Natl. Acad. Sci. USA 82:732-736 (1985).
Campbell et al., J. Mol. Biol. 180:1-19 (1984).
Carroll & Clarke, Nucleic Acids Res. 12:2461 (1984).
Centrella and Lucas-Lenard, J. Virology 41:781-791 (1982),Centrella and Lucas-Lenard, J. Virology 41:781-791 (1982).
Chang et al., J. Gen. Virol. 70:3269-3280 (1989).
Chang et al., Proc. Natl. Acad. Sci. USA 87:5158-5162 (1990).Chang et al., Proc. Natl. Acad. Sci. USA 87:5158-5162 (1990).
Chien et al., Proc. Natl. Acad. Sci. USA 88:9578-9582 (1991).
Choo et al., Proc. Natl. Acad. Sci. USA 88:2451-2455 (1991).
Christianson et al., Genetics 110:119-122 (1992).
Clarke et al., Eur. J. Biochem. 193:635-641 (1990).
Clarke et al., Nucl. Acids Res. 19:243-248 (1991).
Cohen et al., J. Virol. 61:50-59 (1987).
Cohen et al., Proc. Natl. Acad. Sci. USA 84:2497-2501 (1987).
Coward et al., “Yeast Cells are Incapable of Translating RNAs Containing the Pollovirus 5′ Untranslated Region: Evidence for a Translational Inhibitor,” J. Virol. 1992 66(1):286-295.
Cullen, Cell 46:973 (1986).
Del Angel et. al., Proc. Natl. Acad. Sci. USA 86:8299-3803 (1989).
Deuchler et al., Proc. Natl. Acad. Sci. USA 84:2605-2609 (1987).
Dinman and Wickner, “Ribosomal Frameshifting Efficiency and gag/gag-pol Ratio Are Critical for Yeast M.sup.1 Double Stranded RNA Virus Propagation,” J. Virol. 66:3699 (1992).
Dolph et al., J. Virology 62:2059-2066 (1988).
Drug and Market Development, vol. 3. No. 9, pp. 174-180 (Feb. 15, 1993).
Duke et al., “Sequence and Structural Elements That Contribute to Efficient Encephalomyocarditis Virus RNA Translation,” Journal of Virology 66:1602-1609 (1992).
Earie et al., J. Gen. Virol. 69:253-263 (1988).
Edery et al., Cell 56:303-312 (1989).
Etchison et al., J. Biol. Chem. 257:14806-14810 (1982).
Fields and Song, Nature, 340:245-246 (1989).
Fiers et al., J. Supramol Struct Cell Biochem 5:357 (1981).
Forss et al., Nucleic Acids Res. 12:6587 (1984).
Gambarl et al., Int'l J. Pharm. 72:251-258 (1991).
Galderisi et al., Expert Opinion on Emerging Drugs 6(1):69-79 (2001) Abstract.
Galibert et al., Nature 281:646-650 (1979).
Garfinkel and Katze, J. Biol. Chem. 267:9383-9390 (1992).
Geary RS, Yu RZ, Levin AA, Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs. Apr. 2001;2(4):562-73 (Abstract).
Geballe and Mocarski, J. Virology 62:3334-3340 (1988).
Grinell and Wagner, J. Virology 48:88-101 (1983).
Gunnery et al., “Tat-Responsive Region RNA of Human Immunodeficiency Virus 1 Can Prevent Activation of the Double-Stranded-RNA-Activated Protein Kinase,” Proc. Natl. Acad. Sci. USA 87:8687-8691 (1990).
Gura, Science, vol. 270, pp. 575-577, Oct. 27, 1995.
Guilerrez et al., “Transient Inhibition of Foot-and-Mouth Disease Virus Infection of BHK-21 Cells by Antisense Oligonucleotides Directed Against the Second Functional Initiator AUG,” Antiviral Research 22:1-13 (1993).
Halbert et al., J. Virology 86:250-257 (1985).
Hambidge SJ, and Sarnow P. “Terminal 7-methyl-guanosine cap structure on the normally uncapped 5′ noncoding region of pollovirus mRNA inhibitis its translation in mammalian cells.” J Virol. Nov. 1991;65(11):6312-5.
Han et al., Proc. Natl. Acad. Sci. USA 88:1711-1715 (1991).
Hanecak, R. et al., J. Virol. 70(8):5203-12 (Aug. 1996).
Herman, “Alternatives for the Initiation of Translation,” TIBS 14:219-222 (1989).
Hershey, “Translational Control in Mammalian Cells,” Ann. Rev. Biochem. 60:717-755 (1991).
Hershey, “Introduction to Translational Initiation Factors and Their Reulation by Phospharylation,” Seminars in Virology 4:201-207 (1993).
Huang and Schneider, Cell 65:271-280 (1991).
Hughes et al., J. Gen. Virol. 69:49-58 (1988).
Hughes et al., J. Gen. Virol. 67:2093-2102 (1986).
Hughes et al., J. Gen. Virol. 70:2943-2952 (1989).
Iizuka et al., Virology 156:64.
Imani and Jacobs, Proc. Natl. Acad. Sci. USA 85:7887-7891 (1988).
Inchauspe et al., Proc. Natl. Acad. Sci. USA 88:10293 (1991).
Inglis, Mol. Cell. Biol. 2:1644-1648 (1982).
Jacks et al., “Characterization of Ribosomal Frameshifting in HIV-1 gag-pol expression,” Nature 331:280 (1988).
Jackson, “Initation Without and End,” Nature 353:14-15 (1991).
Jackson et al., “The Novel Mechanism of Initiation of Picornavirus RNA Translation,” Trends Biochem. Sci. 15:477-482 (1990).
Jang et al., Enzyme 44:292-309 (1990).
Jang and Wimmer, Genes Dev. 4:1560-1572 (1990).
Jang et al., J. Virol. 63:1651 (1989).
Jang SK, et al., “A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation.” J Virol. Aug. 1988;62(8):2636-43.
Jean-Jean et al., J. Virology 63:5451-5454 (1989).
Jenkins, J. Gen. Virol 68:1835-1848 (1987).
Kato et al., Proc. Natl. Acad. Sci. USA 87:9524-9528 (1990).
Katze, J. Interferon Res. 12:241-248 (1992).
Katze, “Games Viruses Play: a Strategic Initiative Against the Interferon-Induced dsRNA Activisted 68,000 M.sub.r Protein Kinase,” Seminars in Virology 4:259-268 (1993).
Katze et al., J. Virology 62:3710-3717 (1988).
Kozak; “The Scanning Model for Translation: An Update,” J. Cell. Biol. 108:229-241 (1989).
Kozak, “A
Katze Michael G.
Mathews Michael B.
Miles Vincent J.
Watson Julia C.
Witherell Gary
Diehl James J.
Francis Carol L.
Guzo David
Keddie James S.
Rigel Pharmaceuticals Inc.
LandOfFree
Method for selective inactivation of viral replication does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for selective inactivation of viral replication, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for selective inactivation of viral replication will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4019767